MANH
Manhattan Associates, Inc.
MANH's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over MANH overall, supported by stronger modeled upside and stronger valuation.
MANH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
MANH's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
MANH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 43x | $256 | — |
| Cheap | 52x | $187 | -27% |
| Fair | 72x | $257 | +0.3% |
| Current | 72x | $256 | — |
| Expensive | 88x | $312 | +22% |
Historical ranges are pointers, not guarantees.
MANH's PE is in its fair range at 72x. If earnings grow as analysts expect, today's price would be 43x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over MANH in the historical PE scenario, which offers more potential upside but is not a forecast.
MANH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
MANH has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
MANH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.01 | +68% |
| Q3 2026 | $3.57 | +1.7% |
| Q2 2026 | $3.49 | -2.5% |
| Q1 2026 | $3.57 | +2% |
| Q4 2025 | $3.60 | +2.6% |
| Q3 2025 | $3.51 | -0.3% |
| Q2 2025 | $3.58 | +9.1% |
| Q1 2025 | $3.50 | +14% |
| Q4 2024 | $3.51 | +24% |
MANH earned $3.57 per share over the past year, up 1.7% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over MANH on earnings, with more consistent year-over-year improvement.
MANH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $306.2M | +11% |
| Q2 2026 | $297.8M | +9.3% |
| Q1 2026 | $282.2M | +7.4% |
| Q4 2025 | $270.4M | +5.7% |
| Q3 2025 | $275.8M | +3.4% |
| Q2 2025 | $272.4M | +2.7% |
| Q1 2025 | $262.8M | +3.2% |
| Q4 2024 | $255.8M | +7.4% |
MANH's revenue has grown year over year for 23 quarters in a row: $306M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -1 points |
| Q2 2026 | 22% | -4.9 points |
| Q1 2026 | 23% | -1 points |
| Q4 2025 | 25% | +1.1 points |
| Q3 2025 | 27% | -0.7 points |
| Q2 2025 | 27% | +1.4 points |
| Q1 2025 | 24% | +1.4 points |
| Q4 2024 | 24% | -1 points |
MANH's operating margin was 26% last quarter, down 1 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over MANH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over MANH on profitability, with a higher operating margin.
MANH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67.6M | -22% |
| Q2 2026 | $89.7M | +28% |
| Q1 2026 | $79.9M | +7.5% |
| Q4 2025 | $142.4M | +40% |
| Q3 2025 | $87.2M | +42% |
| Q2 2025 | $70.1M | -1.4% |
| Q1 2025 | $74.4M | +42% |
| Q4 2024 | $101.6M | +18% |
MANH's free cash flow has been positive every quarter for seven years: $380M over the past year, up 14% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over MANH on cash flow, with more consistent year-over-year improvement.
MANH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -265K shares |
| 1 year | -3.6% | -2.2M shares |
| 3 years | -5.7% | -3.6M shares |
| 5 years | -8.6% | -5.5M shares |
| Available history | -9.4% | -6.1M shares |
MANH has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $50.5M |
| Q2 2026 | $127.1M |
| Q1 2026 | $179.4M |
| Q4 2025 | $77M |
| Q3 2025 | $51.5M |
| Q2 2025 | $50.2M |
| Q1 2025 | $136.4M |
| Q4 2024 | $45.2M |
MANH spent $434M buying back its own shares over the past year, up 53% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
MANH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
MANH has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
MANH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.2 | Overbought |
| Stochastic | 90.5 | Overbought |
MANH's weekly RSI is 74 (overbought) and its Stochastic is 90 (overbought).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
MANH PE vs Technology Sector
| Metric | MANH | Sector median | Relative |
|---|---|---|---|
| PE | 72x | 28x | 158% above |
| PE % | 49 | 35 | 14 pts above |
MANH is trading at 72x earnings, a 158% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over MANH on valuation relative to its sector.
MANH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $229.1 | 12% above |
| 20 week MA | $205.1 | 25% above |
| 50 week MA | $171.3 | 50% above |
| 100 week MA | $186.4 | 38% above |
| 200 week MA | $201.4 | 27% above |
MANH has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
MANH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.6 | $106.6 | +32% |
| 2021 | $106.6 | $155.3 | +46% |
| 2022 | $155.3 | $120.0 | -23% |
| 2023 | $120.0 | $215.3 | +80% |
| 2024 | $215.3 | $275.2 | +28% |
| 2025 | $275.2 | $176.4 | -36% |
| 2026 YTD | $176.4 | $256.4 | +45% |
MANH has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.